Opexas CEO Invited to Present at Two Cell Therapy Forums in Asia During September, 2011

THE WOODLANDS, Texas (September 19, 2022) Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing Tovaxin, a novel T-cell therapy for multiple sclerosis (MS), today announced that Neil K. Warma, Opexas President and Chief Executive Officer, has been invited to deliver a presentation at The Phacilitate Cell & Gene Therapy Forum Asia 2011 at the Marina Bay Sands Hotel in Singapore. This years Forum, which is taking place on September 19, 2011, is titled Delivering the Strategic Keys to Capitalizing on World-class Cell & Gene Therapy Manufacturing Opportunities in Asia & Australia. Mr. Warmas presentation will occur at 12:40 PM Singapore time.

Mr. Warma will also deliver a keynote presentation at the 2011 Annual Zhong Guancun Forum for Innovation & Development at the Beijing International Conference Center, Beijing, China, which will take place from September 29-30, 2011. Mr. Warmas presentation, titled Cell Therapy: Revolutionizing Disease Treatment, will occur on September 29th at 4:10 PM Beijing time.

About Opexa

Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. The Companys leading therapy, Tovaxin, is a personalized cellular immunotherapy treatment that is in late stage clinical development for MS. Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time.

Opexa is preparing for a Phase III clinical trial with Tovaxin in Relapsing-Remitting Multiple Sclerosis (RRMS) following the completion of a Phase IIb clinical study in 150 patients with MS. Data from this clinical study show evidence that RRMS patients treated with Tovaxin saw overall clinical and disability benefits over the placebo group, including a clinically relevant decrease in the Annualized Relapse Rate (ARR), and improvement in disability score (EDSS), as well as an excellent safety profile with no serious adverse events related to Tovaxin treatment. In addition, Opexa is evaluating opportunities to advance Tovaxin through clinical development in Secondary Progressive Multiple Sclerosis (SPMS), an area with high unmet medical need.

For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com